These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 21559811)
1. Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. Cortelazzo S; Intermesoli T; Oldani E; Ciceri F; Rossi G; Pogliani EM; Mattei D; Romani C; Cortelezzi A; Borlenghi E; Corti C; Peruta B; Spinelli O; Rambaldi A; Bassan R Ann Hematol; 2012 Jan; 91(1):73-82. PubMed ID: 21559811 [TBL] [Abstract][Full Text] [Related]
2. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ; Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402. Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M; Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients]. Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562 [TBL] [Abstract][Full Text] [Related]
5. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688 [TBL] [Abstract][Full Text] [Related]
6. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980 [TBL] [Abstract][Full Text] [Related]
8. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation? Willemze R; Labar B Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726 [TBL] [Abstract][Full Text] [Related]
9. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108 [TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891 [TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
13. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. Thomas X; Boiron JM; Huguet F; Dombret H; Bradstock K; Vey N; Kovacsovics T; Delannoy A; Fegueux N; Fenaux P; Stamatoullas A; Vernant JP; Tournilhac O; Buzyn A; Reman O; Charrin C; Boucheix C; Gabert J; Lhéritier V; Fiere D J Clin Oncol; 2004 Oct; 22(20):4075-86. PubMed ID: 15353542 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. Bassan R; Rossi G; Pogliani EM; Di Bona E; Angelucci E; Cavattoni I; Lambertenghi-Deliliers G; Mannelli F; Levis A; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Borghero C; Romani C; Spinelli O; Tosi M; Oldani E; Intermesoli T; Rambaldi A J Clin Oncol; 2010 Aug; 28(22):3644-52. PubMed ID: 20606084 [TBL] [Abstract][Full Text] [Related]
15. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients]. Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547 [TBL] [Abstract][Full Text] [Related]
16. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system. Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994 [TBL] [Abstract][Full Text] [Related]
18. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545 [TBL] [Abstract][Full Text] [Related]
19. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099 [TBL] [Abstract][Full Text] [Related]